Affinium Pharmaceuticals, Ltd

Quick facts

Phase 2 pipeline

• AFN-12520000 · Diabetes
  AFN-12520000 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Affinium Pharmaceuticals, Ltd portfolio CI brief
• Affinium Pharmaceuticals, Ltd pipeline updates RSS